BeiGene Expands Presence in Middle East and North Africa Region with Opening of United Arab Emirates Office

 

BeiGene Expands Presence in Middle East and North Africa Region with Opening of United Arab Emirates Office

October, 2023–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide,today announced the first step in the company’s expansion inthe Middle East and North Africa (MENA) region with the formal opening of its office in Dubai, United Arab Emirates.

Founded in 2010, BeiGene has built one of the largest and most efficient oncology research teams in the world, with a portfolio of 17 approved assets (3 internally developed) and a broad and deep pipeline focused on haematology and solid tumours with the potential to address 80 per cent of the world's cancers by incidence.

The new officeis located within Dubai Science Park, the region’s leading science-focused business community that is home to more than 450 customers and 5,500 professionals, and will house BeiGene’s administrative, commercial, and medical colleagues.

"Our expansion into the Middle East and North Africa region is a significant step in our company’s ongoing global expansion and an opportunity to reinforce BeiGene's commitment to deliver innovative, affordable and accessible medicines to more patients around the world,” said Jurij Petrin, Head of New Market Development at BeiGene. "Dubai, renowned as the center of regional and international trade in the United Arab Emirates,isthe ideal location for our first office in the region, signalling our growing presence in MENA and enabling us to better serve patients in the area.”

"We're thrilled to announce our expansion into the United Arab Emirates, a pivotal location in the worldwide fight against cancer. This move marks our commitment to MENA, and we're eager to grow our talented team as we introduce innovative medicines to the region," said Mohammed Al-Kapany, General Manager, MENA. "Our presence at Dubai Science Park, with its state-of-the-art facilities, will best support our team and collaborations within the dynamic regional landscape to ensure patients across the region are able to equally access our innovative therapies."

Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group, said: “Cancer remains one of the leading causes of death worldwide, affecting millions of people and their families every year. Greater collaboration in the healthcare and biotechnology sector is essential to deliver breakthrough innovations that can improve survival rates and long-term outcomes for patients.

“Dubai Science Park is committed to making a meaningful impact in cancer treatment and nurturing innovative partnerships within the healthcare and biotechnology communities to benefit patients around the world. We are aligned with the goals of Dubai Economic Agenda ‘D33’, Dubai Research & Development Programme, and ‘We the UAE 2031’ vision to localisescientific advancements that deliver global impact, andwelcomeBeiGene’s collaborationin our endeavour to deliver healthcareadvancements across the world.”

 

BeiGene will hosta ceremony today to celebrate the formal opening of the office,welcoming a number of stakeholders from across the government, healthcare and business sectors, as well asthe patient community.

Through modern laboratories, innovation centres, co-working spaces, and a rich network of globally connected industry peers, Dubai Science Park’s ecosystem enables and empowers R&D efforts that can unlock efficient and advanced treatment options to improve patient outcomes in cancer cases.

Dubai Science Park is part of TECOM Group’s portfolio of 10 districts that includes Dubai Internet City, Dubai Media City, Dubai Studio City, Dubai Production City, Dubai Knowledge Park, Dubai International Academic City, Dubai Design District (d3), and Dubai Industrial City.

About BeiGene

BeiGene is a global biotechnology company that is discovering and developing innovative oncology treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn and X (formerly known as Twitter).

ENDS

About TECOM Group PJSC

TECOM Group has been developing strategic, sector-focused business districts across the emirate of Dubai since 1999. TECOM Group is well-positioned to continue playing an integral role in cementing Dubai’s status as a global business and talent hub.

The TECOM Group portfolio consists of 10 business districts catering to 6 vital knowledge-based economic sectors, including design, education, manufacturing, media, science, and technology. The Group provides a varied and tailor-made leasing portfolio – which includes offices, co-working spaces, warehouses, and land – to over 10,000 customers and more than 105,000 professionals.

TECOM Group offers additional value-added services to deliver a competitive and attractive environment for businesses and entrepreneurs to thrive in and to facilitate engagement between the districts’ community members. Government and corporate services are made available through an integrated smart services platform, ’axs’, which enhances the ease of doing business and provides community members with a seamless experience.

TECOM Group also provides industry-specialised facilities, including media production studios, laboratories, and higher education campuses. in5, its enabling platform for entrepreneurs and start-ups, offers innovation centres supporting tech, media, and design start-ups and SMEs. Its future-focused co-working spaces D/Quarters deliver stimulating work environments for tenants, and the ‘GoFreelance’ package serves freelancers.

For more information, please visit www.tecomgroup.ae.

About Dubai Science Park

Founded in 2005, Dubai Science Park is a vibrant, holistic community part of TECOM Group PJSC dedicated to supporting customers in the life, energy, and environmental sciences. With its ample office and laboratory space and robust infrastructure, Dubai Science Park has created an enabling science-focused ecosystem that is home to major international, regional, and local companies.

By fostering growth, creativity, research, and innovation in the areas of human, plant, material, environmental, and energy sciences, Dubai Science Park aims to play a significant role in facilitating a more sustainable and self-sufficient future that maximises the use of indigenous resources and talent. 

For more information, please visit www.dsp.ae.   

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s future global expansion, including its presence and commitment in MENA; BeiGene’s ability to deliver innovative, afforadable and accessible medicines to more patients around the world; whether the Dubai office will allow BeiGene to better serve patients in the area and provide equal access to innovative therapies; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.